Core Viewpoint - Jichuan Pharmaceutical's subsidiary has received approval for a new drug, which is expected to positively impact the company's future development [1] Group 1: Drug Approval - Jichuan Pharmaceutical announced that its wholly-owned subsidiary, Jichuan Limited, has received a drug registration certificate from the National Medical Products Administration for the drug Marcilosavir Tablets [1] - The drug is classified as a Class 1 new drug and is a next-generation polymerase acidic protein (PA) nuclease inhibitor with broad-spectrum antiviral properties against influenza viruses [1] - The approved indication is for the treatment of previously healthy adults with uncomplicated influenza A and B [1] Group 2: Market Development and Uncertainties - The approval of this cooperative product is expected to have a positive effect on the company's future development [1] - However, the drug's market launch will require a development cycle and is subject to uncertainties influenced by pharmaceutical industry policies and procurement bidding [1]